Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,788.80
(
0.70%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.95
(
0.73%
)
Bitcoin
80,560.00
(
-0.61%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 148813

Thursday, 10/04/2012 9:52:20 PM

Thursday, October 04, 2012 9:52:20 PM

Post# of 257566
Teva halts Rituxan FoB program:

http://www.haaretz.com/business/teva-halts-tests-of-cancer-drug-biosimilar.premium-1.468148

It’s unclear whether this was a technical decision or a business decision. It could well be the latter insofar as there are multiple companies vying for non-interchangeable Rituxan FoB’s, so the profit margins after sales and marketing costs would seem to be meager.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today